- SCU Home Page
- About SCU
- On Campus
- News & Info
New Science Ventures
Grace Colón has over 25 years experience in biopharma, genomics, health care and industrial biotechnology. Her executive roles have spanned a broad range of functions in companies ranging from start-ups to publicly traded corporations.
She recently joined New Science Ventures as a Partner focusing on biotechnology investments. She is also CEO and President of InCarda Therapeutics and co-founder and Executive Chairman of Pyranose Biotherapeutics, Prior to that she was President of the Industrial Products Division and Corporate SVP at Intrexon Corporation, where she established a new division focused on applying Intrexon’s synthetic biology platform to bioindustrial applications such as biofuels and renewable chemicals. Preceding Intrexon she held of variety of senior leadership roles at Gilead Sciences, including leading the Clinical Operations, Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was VP Corporate Planning at Affymetrix, where she was responsible for strategic planning and project management. She also served as founding COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Earlier in her career she was a consultant with McKinsey & Co., where she served clients in health care, biotech, high tech and venture capital.
Grace received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was a National Science Foundation Fellow, and a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.